Adamas Pharmaceuticals (Nasdaq: ADMS) looked set to open on Friday morning around 55% up on Thursday’s closing price, with its early-morning value at above $22 compared to the previous $14.23.
The reason for the investor frenzy was the Californian biotech firm’s announcement that the US Food and Drug Administration (FDA) had approved Gocovri (amantadine) as the first medicine to treat dyskinesia in patients with Parkinson's disease.
Most patients diagnosed with Parkinson’s are treated with levodopa, use of which often leads to dyskinesia - involuntary movements that are non-rhythmic, purposeless and unpredictable.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze